Leah Park

Articles by Leah Park

53 U.S. Patient Perspectives on Capivasertib Plus Fulvestrant: Dosing, Tolerability, and Blood Glucose Monitoring From Qualitative Interviews

ByLeah Park,Emily Mulvihill,Alexandra Kissling,Michael F. Barry

June 21st 2026

Qualitative interviews with 43 patients on capivasertib plus fulvestrant found the 4-on/3-off dosing schedule broadly acceptable, while identifying gaps in hyperglycemia recognition and willingness to use supportive medications.

140 Real-World Pharmacological Management of Hyperglycemia in HR-Positive/HER2-Negative Metastatic Breast Cancer Treated With Capivasertib or Alpelisib

ByNeil M. Iyengar, MD,Ravi Potluri,Anirban Ghosh,Leah Park

May 1st 2026

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

ByChia Jie Tan,Connor Willis,Trang Au,Matthew Schabath, PhD,Chenghui Li,Kristen Kelley,Xiaoqing Xu,Leah Park,Clara Lam,Sandhya Mehta,Jackie Kwong,Diana Brixner,David Stenehjem

April 17th 2025

Leah Park

Articles by Leah Park

53 U.S. Patient Perspectives on Capivasertib Plus Fulvestrant: Dosing, Tolerability, and Blood Glucose Monitoring From Qualitative Interviews

140 Real-World Pharmacological Management of Hyperglycemia in HR-Positive/HER2-Negative Metastatic Breast Cancer Treated With Capivasertib or Alpelisib

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Afami-cel in Metastatic Synovial Sarcoma

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview

Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup

How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?